Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Helius Medical Technologies Inc HSDT

Helius Medical Technologies, Inc. is a neurotech company in the medical device field. It is focused on neurologic deficits using orally applied technology platform that amplifies the brain’s ability to engage physiologic compensatory mechanisms enhancing the lives of people dealing with neurologic diseases. It develops, licenses, or acquires non-implantable technologies targeted at reducing symptoms of neurological disease or trauma. Its product Portable Neuromodulation Stimulator (PoNS) is a non-implantable medical device, inclusive of a controller and mouthpiece, which delivers mild electrical stimulation to the surface of the tongue to provide treatment of gait deficit and chronic balance deficit. PoNS Therapy is integral to the overall PoNS solution and is the physical therapy applied by patients during use of the PoNS neuromodulation stimulator. PoNS is used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only.


NDAQ:HSDT - Post by User

Post by StockMarketBullon Nov 18, 2018 9:38pm
140 Views
Post# 28992380

Russia results of CP study with PoNS

Russia results of CP study with PoNSRussia results of CP study with PoNS was presented.
In international congress 1-2 November this year.  Here are the main points translated:

“Materials and methods. Standard scales GMFSC, FMS, Ashvotr Scale, Berg Scale were used for the evaluation, and an EEG study was also conducted. The study involved 134 patients, aged 2 to 6 years with a diagnosis of cerebral palsy. Spastic diplegia. All patients had intact intelligence, did not have convulsive seizures. The test group of children was 96 people. All children in this group received standard treatment and additionally translingual neurostimulation of the brain. The control group consisted of 40 people who received only standard therapy.

Results. The results obtained proved the safety and efficacy of this method in patients with cerebral palsy. A positive result was observed in reducing spasticity and improving balance and balance control in both groups, but was most pronounced in the group of subjects, as evidenced by statistically significant results. Also in the group of subjects, the cumulative nature of the results of therapy was noted, which indicates that the results achieved as a result of the combination therapy remain in the intervals between the courses. This study supports our hypothesis that non-invasive translingual neurostimulation is, indeed, facilitates and increases the effectiveness of standard physical therapy. This method of neurostimulation effectively activates the brain structures involved in the mechanisms of sensorimotor integration. Findings. The use of neurostimulation with the help of the PONS device, in combination with therapeutic gymnastics (targeted exercises), can improve the efficiency of the restoration of motor functions and the development of motor skills. This study opens up broad prospects for the use and development of this method in children with cerebral palsy.”

Source:
https://association-dcp.ru/wp-content/uploads/2018/11/tezis_2018.pdf
Bullboard Posts